Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for obesity
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on obesity or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on obesity and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Serum soluble receptor of advanced glycation end products and risk of metabolic syndrome in Egyptian obese women 28900377 2018 11 13 1611-2156 16 2017 EXCLI journal EXCLI J Serum soluble receptor of advanced glycation end products and risk of metabolic syndrome in Egyptian obese women. 973-980 10.17179/excli2017-275 Obesity is one of the diagnostic criteria of metabolic syndrome (MS). It is correlated with insulin resistance (IR) and high vascular risk as well. Advanced glycation end products (...) (AGEs) and their receptor (RAGE) play an important role in abnormal metabolic components in obese women. This study aimed to explore the serum levels of sRAGE in Egyptian obese women and compare with healthy non-obese controls and investigate the relationship between serum sRAGE, metabolic parameters, and obesity complications. The soluble form of receptor for advanced glycation end products (sRAGE), anthropometry, metabolic and biochemical biomarkers were measured in 100 obese women and 100 age
Successful treatment with Korean herbal medicine and lifestyle management in an obese woman with polycystic ovarian syndrome 28951847 2018 11 13 2213-4220 6 3 2017 Sep Integrative medicine research Integr Med Res Successful treatment with Korean herbal medicine and lifestyle management in an obese woman with polycystic ovarian syndrome. 325-328 10.1016/j.imr.2017.06.002 In Korea, herbal remedies have been widely used to treat polycystic ovarian syndrome (PCOS). We report the case of a woman (...) with obese-type PCOS who was successfully treated with Korean herbal medicine (KHM) and lifestyle management. A 23-year-old female patient was first examined at our clinic in April 2015. She had amenorrhea for the previous 9 months and presented with obesity and abnormal reproductive hormone levels. She was treated using KHM and lifestyle management. We observed her menstrual cycles and re-evaluated her hormonal levels during the treatment. After KHM therapy, her body weight decreased from 88.2 kg
Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. Importance: Based on year 2000 Centers for Disease Control and Prevention growth charts, approximately 17% of children and adolescents aged 2 to 19 years in the United States have obesity, and almost 32% of children and adolescents are overweight or have obesity. Obesity in children and adolescents is associated with morbidity such as mental health and psychological issues, asthma (...) , obstructive sleep apnea, orthopedic problems, and adverse cardiovascular and metabolic outcomes (eg, high blood pressure, abnormal lipid levels, and insulin resistance). Children and adolescents may also experience teasing and bullying behaviors based on their weight. Obesity in childhood and adolescence may continue into adulthood and lead to adverse cardiovascular outcomes or other obesity-related morbidity, such as type 2 diabetes. Subpopulation Considerations: Although the overall rate of child
Risk of major congenital malformations in relation to maternal overweight and obesity severity: cohort study of 1.2 million singletons. Objective To estimate the risks of major congenital malformations in the offspring of mothers who are underweight (body mass index (BMI) <18.5), overweight (BMI 25 to <30), or in obesity classes I (BMI 30 to <35), II (35 to <40), or III (≥40) compared with offspring of normal weight mothers (BMI 18.5 to <25) in early pregnancy. Design Population (...) ); obesity class I, 3.8% and 1.12 (1.08 to 1.15), obesity class II, 4.2% and 1.23 (1.17 to 1.30), and obesity class III, 4.7% and 1.37 (1.26 to 1.49). The risks of congenital heart defects, malformations of the nervous system, and limb defects also progressively increased with BMI from overweight to obesity class III. The largest organ specific relative risks related to maternal overweight and increasing obesity were observed for malformations of the nervous system. Malformations of the genital
Health Effects of Overweight and Obesity in 195 Countries over 25 Years. Background Although the rising pandemic of obesity has received major attention in many countries, the effects of this attention on trends and the disease burden of obesity remain uncertain. Methods We analyzed data from 68.5 million persons to assess the trends in the prevalence of overweight and obesity among children and adults between 1980 and 2015. Using the Global Burden of Disease study data and methods, we also (...) quantified the burden of disease related to high body-mass index (BMI), according to age, sex, cause, and BMI in 195 countries between 1990 and 2015. Results In 2015, a total of 107.7 million children and 603.7 million adults were obese. Since 1980, the prevalence of obesity has doubled in more than 70 countries and has continuously increased in most other countries. Although the prevalence of obesity among children has been lower than that among adults, the rate of increase in childhood obesity in many
Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program 28473337 2017 05 05 2017 05 05 1935-5548 2017 May 04 Diabetes care Diabetes Care Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity 28266779 2017 03 07 2017 05 05 1463-1326 2017 Mar 07 Diabetes, obesity & metabolism Diabetes Obes Metab Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. 10.1111/dom.12932 The aim of this trial was to investigate the mechanism of action for body weight loss (...) with semaglutide. This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity. Ad libitum energy intake, ratings of appetite, thirst, nausea and well-being, control of eating, food preference, resting metabolic rate, body weight and body composition were assessed. After a standardised breakfast, semaglutide, compared with placebo, led to a lower ad
Bisphenol A substitutes and obesity in US adults: analysis of a population-based, cross-sectional study 29308453 2018 11 13 2542-5196 1 3 2017 Jun The Lancet. Planetary health Lancet Planet Health Bisphenol A substitutes and obesity in US adults: analysis of a population-based, cross-sectional study. e114-e122 10.1016/S2542-5196(17)30049-9 Bisphenol F (BPF) and bisphenol S (BPS) are increasingly used to substitute bisphenol A (BPA), a widespread environmental endocrine disruptor and putative (...) obesogen. However, studies on effects of BPF and BPS on obesity in humans are lacking. We examined the associations of BPA, BPF, and BPS exposure with obesity in U.S. adults. We included 1,521 participants aged 20 years or older from a cross-sectional study, the National Health and Nutrition Examination Survey 2013-2014. Urinary BPA, BPF, and BPS concentrations were measured using on-line solid phase extraction coupled to high performance liquid chromatography and tandem mass spectrometry. We used
Low prevalence of obesity in BehÃ§etâ€™s disease is associated with high obestatin level 28638683 2018 11 13 2147-9720 4 2 2017 Jun European journal of rheumatology Eur J Rheumatol Low prevalence of obesity in Behçet's disease is associated with high obestatin level. 113-117 10.5152/eurjrheum.2017.160095 Chronic inflammatory diseases are associated with altered body composition. Ghrelin has anti-inflammatory effects, and its level is altered in obesity and inflammatory diseases. The aim (...) of the study was to evaluate the prevalence of obesity and ghrelin and obestatin levels in patients with Behçet's disease (BD). One hundred and forty-three (143) patients with BD and 112 healthy controls (HC) were enrolled. Participants were subdivided according to the body mass index (BMI) as lean (<18.5 kg/m 2 ), normal weight (18.5-24.9 kg/m 2 ), overweight (25-29.9 kg/m 2 ) and obese (≥30 kg/m 2 ). In addition to the routine evaluations (fasting blood glucose, lipid profile, and kidney and liver
Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120â€ˆ813 adults from 16 cohort studies from the USA and Europe 28626830 2018 11 13 2468-2667 2 6 2017 Jun The Lancet. Public health Lancet Public Health Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe. e277-e285 10.1016/S2468-2667(17)30074-9 Although overweight (...) and obesity have been studied in relation to individual cardiometabolic diseases, their association with risk of cardiometabolic multimorbidity is poorly understood. Here we aimed to establish the risk of incident cardiometabolic multimorbidity (ie, at least two from: type 2 diabetes, coronary heart disease, and stroke) in adults who are overweight and obese compared with those who are a healthy weight. We pooled individual-participant data for BMI and incident cardiometabolic multimorbidity from 16
Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults. BACKGROUND: Obesity causes frailty in older adults; however, weight loss might accelerate age-related loss of muscle and bone mass and resultant sarcopenia and osteopenia. METHODS: In this clinical trial involving 160 obese older adults, we evaluated the effectiveness of several exercise modes in reversing frailty and preventing reduction in muscle and bone mass induced by weight loss. Participants were randomly assigned (...) ]) (P<0.05 for all comparisons). Exercise-related adverse events included musculoskeletal injuries. CONCLUSIONS: Of the methods tested, weight loss plus combined aerobic and resistance exercise was the most effective in improving functional status of obese older adults. (Funded by the National Institutes of Health; LITOE ClinicalTrials.gov number, NCT01065636 .).
Major Pathophysiology in Prediabetes and Type 2 Diabetes: Decreased Insulin in Lean and Insulin Resistance in Obese 29264527 2018 11 13 2472-1972 1 6 2017 Jun 01 Journal of the Endocrine Society J Endocr Soc Major Pathophysiology in Prediabetes and Type 2 Diabetes: Decreased Insulin in Lean and Insulin Resistance in Obese. 742-750 10.1210/js.2016-1116 Lowering of body mass index (BMI) to ≥25 kg/m 2 as obesity by ADA suggests insulin resistance as a major mechanism of impaired glucose metabolism (...) (IGM) in Asians. However, glimepiride, an insulin secretagogue, delayed onset of type 2 diabetes (DM2) from prediabetes (PreDM), indicating decreased insulin secretion (IS) as a major factor in lean (L; BMI < 27 kg/m 2 ) subjects with IGM. Assessment of IS and insulin resistance (IR) in L and obese (Ob; BMI ≥ 27 kg/m 2 ) subjects with euglycemia (N), PreDM, and new onset DM2. Seventy-five men and 45 women ages 36 to 75 years were divided into six groups: LN, LPreDM, LDM2, ObN, ObPreDM, and ObDM2
Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer 28649659 2018 11 13 2374-4677 3 2017 NPJ breast cancer NPJ Breast Cancer Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer. 19 10.1038/s41523-017-0015-9 Growing evidence indicates that adiposity is associated with breast cancer risk and negatively affects breast cancer recurrence and survival, a paracrine role (...) of mammary adipose tissue being very likely in this process. In contrast to other adipose depots, occurrence of a sub-inflammatory state of mammary adipose tissue defined by dying adipocytes surrounded by macrophages forming crown-like structures in overweight and obese subjects, remains only partially described. In a general population of breast cancer patients (107 patients) mostly undergoing breast-conserving surgery, we found a positive association between patient's body composition, breast
Modifying Alcohol Consumption to Reduce Obesity (MACRO): development and feasibility trial of a complex community-based intervention for men Modifying Alcohol Consumption to Reduce Obesity (MACRO): development and feasibility trial of a complex community-based intervention for men Modifying Alcohol Consumption to Reduce Obesity (MACRO): development and feasibility trial of a complex community-based intervention for men Crombie IK, Cunningham KB, Irvine L, Williams B, Sniehotta FF, Norrie J (...) , Melson A, Jones C, Briggs A, Rice PM, Achison M, McKenzie A, Dimova E & Slane PW Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Crombie IK, Cunningham KB, Irvine L, Williams B, Sniehotta FF, Norrie J, Melson A, Jones C, Briggs A, Rice PM, Achison M, McKenzie A, Dimova E & Slane PW. Modifying Alcohol Consumption to Reduce Obesity (MACRO
Effects of Rapid Weight Loss on Systemic and Adipose Tissue Inflammation and Metabolism in Obese Postmenopausal Women 29264516 2018 11 13 2472-1972 1 6 2017 Jun 01 Journal of the Endocrine Society J Endocr Soc Effects of Rapid Weight Loss on Systemic and Adipose Tissue Inflammation and Metabolism in Obese Postmenopausal Women. 625-637 10.1210/js.2017-00020 Obesity is associated with subclinical white adipose tissue inflammation, as defined by the presence of crown-like structures (CLSs (...) ) consisting of dead or dying adipocytes encircled by macrophages. In humans, bariatric surgery-induced weight loss leads to a decrease in CLSs, but the effects of rapid diet-induced weight loss on CLSs and metabolism are unclear. To determine the effects of rapid very-low-calorie diet-induced weight loss on CLS density, systemic biomarkers of inflammation, and metabolism in obese postmenopausal women. Prospective cohort study. Rockefeller University Hospital, New York, NY. Ten obese, postmenopausal women
Prokineticin Is a New Linker between Obesity and Cardiovascular Diseases 28447033 2018 11 13 2297-055X 4 2017 Frontiers in cardiovascular medicine Front Cardiovasc Med Prokineticin Is a New Linker between Obesity and Cardiovascular Diseases. 20 10.3389/fcvm.2017.00020 Obesity is a fast growing epidemic event worldwide. Fatness is associated with a number of comorbidities, including cardiovascular diseases (CVDs). Although obesity can be heredity in 30-70% cases, the environmental contributions (...) also play an important role in the increasing prevalence of obesity. The relationship between development of obesity and CVD is poorly characterized. Obesity and CVD can also be resulted from a common mechanism such as metabolic, inflammatory, and neurohormonal changes. Prokineticins are defined as cytokines (immunoregulatory proteins), adipokines (adipocyte-secreted hormone), angiogenic (increasing vessel formation), or aneroxic (lowering food intake) hormones. Prokineticin-mediated signaling
The Microbiome in Visceral Medicine: Inflammatory Bowel Disease, Obesity and Beyond 28560232 2018 11 13 2297-4725 33 2 2017 May Visceral medicine Visc Med The Microbiome in Visceral Medicine: Inflammatory Bowel Disease, Obesity and Beyond. 153-162 10.1159/000470892 It has become increasingly evident over the past two decades that the microbiota plays a nurturing role in the development of the immune system. This appears to be important since the amplitude of immune responses has a crucial
The obesity paradox, extreme obesity, and long-term outcomes in older adults with ST-segment elevation myocardial infarction: results from the NCDR 28838094 2018 10 31 2018 11 13 2058-1742 3 3 2017 07 01 European heart journal. Quality of care & clinical outcomes Eur Heart J Qual Care Clin Outcomes The obesity paradox, extreme obesity, and long-term outcomes in older adults with ST-segment elevation myocardial infarction: results from the NCDR. 183-191 10.1093/ehjqcco/qcx010 To investigate (...) the obesity paradox and association of extreme obesity with long-term outcomes among older ST-segment elevation myocardial infarction (STEMI) patients. Nineteen thousand four hundred and ninety-nine patients ≥65 years with STEMI surviving to hospital discharge in NCDR ACTION Registry-GWTG linked to Centers for Medicare and Medicaid Services outcomes between 2007 and 2012 were stratified by body mass index (BMI) (kg/m2) into normal weight (18.5-24.9), overweight (25-29.9), class I (30-34.9), class II (35